This antibody recognizes the C-terminal sequence of beta amyloid peptide 42 and full length beta amyloid peptide 42. The antibody does not cross react with beta amyloid peptide 40 in dot blotting and ELISA. Cross-reactivity to beta amyloid peptide 43 is about 5 % in ELISA.
Cross-Reactivity (Details)
Species reactivity (tested):Human, Primates, Mouse, Rat.
Purification
Protein G affinity purified
Immunogen
KLH conjugated to a short peptide with amino acid sequence corresponding to the C- terminal of beta amyloid peptide 42.
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Reconstitution
Restore with Double distillated water to adjust the final concentration to 1.0 mg/mL.
Buffer
0.01 M PBS pH 7.2
Handling Advice
Avoid repeated freezing and thawing.
Storage
-20 °C
Storage Comment
Store at -20 °C.
Target
beta Amyloid (Abeta)
(Amyloid beta (Abeta))
Alternative Name
Amyloid beta
Background
Amyloid beta peptide 42 (Aβ42) is best known for its role in the formation of senile plaques in the brain of patients with Alzheimer's disease. Aβ42 and Aβ40 are the two major amyloid peptides that are produced after cleavage of amyloid precursor protein by secretases. Aβ42 (42 amino acids) is very fibrillogenic. The beta pleated structure of Aβ42 constituents the initial and key component of the insoluble amyloid fibril in senile plaque. It is widely accepted that Aβ42 contributes to the pathogenesis of Alzheimer's disease. One proposition is that the deposition of amyloid fibril onto the brain tissue results in Alzheimer's disease. Another is that the neurotoxicity of Aβ42 oligomer is the cause of the disease.Synonyms: Amyloid beta peptide